Safety and Efficacy of ABT-510 in Subjects With Advanced Renal Cell Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

May 31, 2003

Conditions
Carcinoma, Renal Cell
Interventions
DRUG

ABT-510/Thrombospondin-1 mimetic

Trial Locations (18)

12208

Albany Regional Cancer Center, Albany

27511

Raleigh Hematology Oncology Clinic, Cary

33486

The Center for Hematology-Oncology, Boca Raton

46227

Central indiana Cancer Center, Indianapolis

48109

University of Michigan, Ann Arbor

60637

University of Chicago Medical Center, Chicago

64111

Kansas City Oncology and Hematology Group, Kansas City

66210

Kansas City Cancer Centers Southwest, Overland Park

Texas Cancer Center, Fort Worth

75246

US Oncology, P.A., Dallas

76104

Texas Cancer Center, Fort Worth

77030

MD Anderson Cancer Center, Houston

85258

Virginia G. Piper Cancer Center, Scottsdale

85724

Arizona Cancer Center, Tucson

90024

UCLA School of Medicine, Los Angeles

90640

Clinical Trials and Research Associates, Montebello

Unknown

Baylor College of Medicine, Houston

Academic Hospital Groningen, Groningen

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Abbott

INDUSTRY